What one share of Dianthus Therapeutics, Inc. /DE/ holds
We are a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients living with severe autoimmune diseases.
Dianthus Therapeutics, Inc. /DE/’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$4.12 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$3.34 |
| Dividends | $0.00 |
| Cash and investments | $2.02 |
| Book value | $21.39 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$32.57 | $0.36 | −$33.61 | — | −$50.69 |
| 2023 | $0.55 | −$8.45 | $0.02 | −$7.17 | $0.00 | — |
| 2024 | $0.19 | −$2.55 | $0.00 | −$2.35 | $0.00 | $11.33 |
| 2025 | $0.05 | −$4.20 | $0.01 | −$3.35 | $0.00 | $11.42 |
Common questions about Dianthus Therapeutics, Inc. /DE/
How much does one share of Dianthus Therapeutics, Inc. /DE/ earn?
Over the last 12 months, Dianthus Therapeutics, Inc. /DE/ lost $4.12 for each share.
Does Dianthus Therapeutics, Inc. /DE/ pay a dividend?
Dianthus Therapeutics, Inc. /DE/ didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Dianthus Therapeutics, Inc. /DE/’s book value per share?
Dianthus Therapeutics, Inc. /DE/’s book value is $21.39 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Dianthus Therapeutics, Inc. /DE/ have?
Each share of Dianthus Therapeutics, Inc. /DE/ has $2.02 of cash and investments, as of June 30, 2026.
What is Dianthus Therapeutics, Inc. /DE/’s free cash flow per share?
−$3.34 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Dianthus Therapeutics, Inc. /DE/ bought back shares?
Dianthus Therapeutics, Inc. /DE/’s share count rose about 4317% from 2022 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.